Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Robert M Jotte
Nab-Paclitaxel/Carboplatin Induction in Squamous NSCLC: Longitudinal Quality of Life While on Chemotherapy
Lung Cancer: Targets and Therapy
Oncology
Related publications
216PD: Nab-Paclitaxel + Carboplatin (Nab-P/C) in Advanced Non-Small Cell Lung Cancer (NSCLC): Outcomes in Elderly Patients (Pts) With Squamous (SCC) Histology
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.16-21 Phase I / II Study of Carboplatin, Nab-Paclitaxel, and Concurrent Radiotherapy for Patients With Locally Advanced NSCLC
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-93 Quality of Life in Patients With Advanced NSCLC Treated in Second- Or Third-Line With Nab-Paclitaxel + Durvalumab: ABOUND.2L+
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
JCSE01.17 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-48 Nab-Paclitaxel Plus Gemcitabine in Advanced NSCLC After Platinum-Based Chemotherapy: Final Results and Caveolin-1 Expression
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.16-08 Weekly Nab-Paclitaxel Plus Carboplatin as Neoadjuvant Therapy for IIIA-N2 Lung Squamous Cell Carcinoma: A Prospective Phase II Study
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Paclitaxel-Carboplatin Chemotherapy Induced Hematologic Toxicities Among Epithelial Ovarian Cancer Patients
Universa Medicina
Quality-Adjusted Survival With Nab -Paclitaxel vs Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis
Clinical Breast Cancer
Cancer Research
Oncology
Nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
Frontiers in Oncology
Cancer Research
Oncology
